GT Biopharma (GTBP) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company developing immuno-oncology products using proprietary TriKE® and Dual Targeting TriKE® platforms to harness and enhance natural killer (NK) cell cancer-killing abilities.

• TriKE® therapeutics are designed for hematologic malignancies, solid tumors, and potentially autoimmune disorders, with scalability for rapid IND-ready candidate production.

• Initial research collaboration with the University of Minnesota; exclusive rights to the TriKE® platform and ongoing IP generation.

Financial performance and metrics

• As of May 30, 2025, 3,147,995 shares of common stock outstanding; company has a history of significant cash use for R&D and expects to need substantial additional capital for future development and commercialization.

• Regained compliance with Nasdaq’s $2.5 million minimum stockholders’ equity requirement as of June 13, 2025, after a period of non-compliance.

• Substantial doubt exists about the ability to continue as a going concern without additional financing; existing cash resources are insufficient for one year of operations from the last annual report date.

Use of proceeds and capital allocation

• Will not receive proceeds from selling stockholders’ sales; may receive proceeds from cash exercise of warrants and up to $20 million from sales under the Committed Equity Facility (CEF).

• Proceeds from warrant exercises and CEF sales intended for working capital and general corporate purposes; specific allocation not yet determined.